Beta bloccanti

<p>Applications Impurity of Bivalirudin, a direct thrombin inhibitor acting as an anticoagulant through inhibition of the enzyme thrombin.<br>References Bertrand, O. et al.: Am. J. Cardio., 110, 599 (2012); Patti, G. et al.: Am. J. Cardio., 110, 478 (2012);<br></p>

<p>Applications Befunolol is a β-adrenergic blocker with an intrinsic sympathomimetic action. But it can work as a β-adrenergic partial agonist in isolated organs.<br>References Nakano, J., et al.: Chem. Pharm. Bull., 36, 1399 (1988); Takayanagi, I., et al.: Gen. Pharmacol., 20, 417 (1989); Koike, K., et al.: Gen. Pharmacol., 25, 1477 (1994)<br></p>

<p>Applications Asperosaponin VI is a steroidal extract with anti-inflammatory and antinociceptive activity. long term use has been seen to attenuate cardiac dysfunction.<br>References Choi, J. et al.: J. Med. Food, 8, 78 (2005); Li, C. et al.: Food. Chem. Toxicol., 8, 1432 (2012);<br></p>

<p>Applications Telmisartan Acyl-β-D-glucuronide is a metabolite of Telmisartan (T017000).<br>References Abe, T., et al.: J. Biol. Chem., 274, 17159 (1999), Hirano, M., et al.: Drug Metab. Dispos., 34, 1229 (2006),<br></p>

<p>Stability Hygroscopic<br>Applications A labelled metabolite of Caffeine.<br>References Suto, M., et al.: Anticancer Drug Des., 6, 107 (1991), Burkart, V., et al.: Nat. Med., 5, 314 (1999), Hassa, P., et al.: J. Biol. Chem., 278, 45145 2003), Veres, B., et al.: J. Pharmacol. Exp. Ther., 310, 247(2004),<br></p>

<p>Stability Hygroscopic<br>Applications The optically active isomer of Carvedilol (C184625), a nonselective ß-adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990),<br></p>

<p>Applications 2-Azidoethanol is used as a reagent in the glycosylation of mono- or polysaccharides. 2-Azidoethanol is also used as a 2’-deoxy-ethynyluridine (EdU) blocker in nuclear DNA, preventing cross reactivity with other antibodies in order to better study its related pathways in the body.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Liboska, R., et al.: PLOS ONE, 7, e51679 (2012); Sun, X., et al.: Biomacromolecules, 3, 1065 (2002)<br></p>

<p>Applications Labelled Diltiazem (D460620). A calcium channel blocher with vasodilating activity. Antianginal; antihypertensive; antiarrhythmic (class IV).<br>References Sato, et al.: Arzneim.-Forsch., 21, 1338 (1971), Smirnov, S.R.: Eur. J. Pharmacol., 360, 81 (1998), Hansson, L., et al.: Lancet, 356, 359 (2000),<br></p>

<p>Applications A new Sildenafil (S435000) analogue.<br>References Balayssac, S., et al.: J. Pharm. Biomed. Anal., 50, 602 (2009),<br></p>

<p>Applications 6-Oxo Simvastatin is an analog of Simvastatin (S485000), a HMG-CoA reductase inhibitor.<br>References Joshua, H., et al.: J. Antibiot., 44, 366 (1991),<br></p>

<p>Impurity Hydrochlorothiazide EP Impurity C<br>Applications N-[[7-(Aminosulfonyl)-6-chloro-2,3-dihydro-1,1-dioxo-4H-1,2,4-benzothiadiazin-4-yl]methyl]-6-chloro-3,4-dihydro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide (Hydrochlorothiazide EP Impurity C) is an impurity in bulk Hydrochlorothiazide. Dimer Impurity C.<br>References Daniels, S.L., et al.: J. Pharm. Sci., 70, 211 (1981), Fang, X., et al.: Pharm. Res., 14, 691 (1997),<br></p>

<p>Applications N6-Isopentenyladenosine has antiproliferative activity on MCF-7 breast cancer cells.<br>References Rajabi, M. et al.; DNA Cell Biol.; 29, 687 (2010)<br></p>

<p>Stability Hygroscopic<br>Applications Labelled Mexiletine (M340800). Antiarrhythmic (class IB).<br>References Singh, E.M., et al.: Br. J. Pharmacol., 44, 1 (1972), Scott, K.N., et al.: Drug Metab. Dispos., 1, 506 (1973), Chew, C.Y.C., et al.: Drugs, 17, 161 (1979), Abounassif, M.A., et al.: Anal. Profiles Drug Subs., 20, 433 (1991),<br></p>

<p>Applications Labelled Torsemide (T548750). Used as a diuretic.<br>References Lesne, M., et al.: In. J. Clin. Pharmacol. Ther. Toxicol., 20, 382 (1982), Brater, D.C., et al.: Clin. Pharmacol. Ther., 42, 187 (1987),<br></p>